OWC Pharmaceutical Research Corp. (OWCP) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
OWC Pharmaceutical Research Corp. (OWCP) trades at $0.00001. OWC Pharmaceutical Research Corp. (OWCP) focuses on the research and development of cannabis-based medical products through its subsidiary One World Cannabis Ltd. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for OWCP: OWCP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OWCP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on OWCP.
How is this calculated? →OWC Pharmaceutical Research Corp. (OWCP) Healthcare & Pipeline Overview
OWC Pharmaceutical Research Corp., operating via One World Cannabis Ltd., specializes in the research and development of cannabis-based medical products. Headquartered in Ramat Gan, Israel, the company targets therapies for conditions such as multiple myeloma, psoriasis, and PTSD, while also providing consulting on international medical cannabis protocols and innovating a soluble tablet delivery system.
What Is the Investment Thesis for OWCP?
OWC Pharmaceutical Research Corp. (OWCP) presents an investment profile centered on its specialized research and development efforts in the rapidly evolving medical cannabis sector. The company's value drivers include its focused pipeline targeting conditions such as multiple myeloma, psoriasis, PTSD, chronic pain, and fibromyalgia, representing significant unmet medical needs. Its innovation in a cannabis soluble tablet delivery system could offer a differentiated product with enhanced patient compliance and bioavailability. Growth catalysts are intrinsically linked to the progression of its R&D pipeline, with successful clinical trial outcomes and subsequent regulatory approvals being critical milestones. The expanding global acceptance and legalization of medical cannabis also provide a tailwind for market penetration. Furthermore, the company's consulting services, advising on international medical cannabis protocols, offer a distinct revenue stream and leverage its specialized knowledge. However, the investment thesis is tempered by significant risks, including the high capital requirements for pharmaceutical R&D, the inherent uncertainties of clinical trials, and the complex, often restrictive, regulatory environment surrounding cannabis. Its listing on the OTC Other tier also implies lower liquidity and transparency, alongside potential challenges in securing consistent funding, as highlighted by its current market capitalization of $0.00B.
Based on FMP financials and quantitative analysis
OWCP Key Highlights
Market Capitalization: $0.00B, indicating a micro-cap or early-stage company valuation.
- Beta: -243.53, suggesting an extremely high inverse correlation to market movements, which may indicate data anomaly or very low liquidity.
- Dividend Yield: None, as the company does not currently distribute dividends to shareholders.
- Employee Count: 9 employees, reflecting a small operational scale focused on specialized R&D.
- Primary Focus: Dedicated research and development of cannabis-based medical products and innovative delivery systems.
Who Are OWCP's Competitors?
OWCP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OWCP's Key Strengths?
Specialized focus on cannabis-based medical product research and development.
- Diverse therapeutic pipeline targeting significant conditions like multiple myeloma and PTSD.
- Innovation in drug delivery with a cannabis soluble tablet system.
- Established consulting services for medical cannabis protocols and regulatory frameworks.
What Are OWCP's Weaknesses?
Small operational scale with only 9 employees, potentially limiting R&D capacity.
- High reliance on external funding for capital-intensive pharmaceutical R&D.
- Trading on the OTC Other tier, implying higher risk, lower liquidity, and limited disclosure.
- Current market capitalization of $0.00B, indicating a very early-stage or distressed financial position.
What Could Drive OWCP Stock Higher?
Positive clinical trial results for any of its cannabis-based therapeutic candidates.
- Successful development and patenting of the cannabis soluble tablet delivery system.
- Announcement of a significant strategic partnership or a new funding round.
- Expansion of its consulting services client base, particularly with governmental bodies.
- Favorable shifts in international medical cannabis regulatory frameworks.
What Are the Key Risks for OWCP?
Financial-distress signal — its Altman Z-Score of -31.25 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- High capital expenditure requirements for pharmaceutical R&D without guaranteed commercial success.
- Failure to secure adequate and consistent funding to sustain long-term research and development efforts.
- Adverse regulatory changes or delays in the approval process for cannabis-based medical products.
- Intense competition from larger, better-funded pharmaceutical and biotech companies in the medical cannabis space.
- Clinical trial failures, delays, or unexpected safety concerns for its drug candidates.
What Are the Growth Opportunities for OWCP?
- Expansion of Therapeutic Pipeline: OWC Pharmaceutical's focus on developing cannabis-based therapies for conditions such as multiple myeloma, psoriasis, PTSD, chronic pain, and fibromyalgia represents a significant growth opportunity. Successful progression of its drug candidates through clinical trials and eventual regulatory approval could unlock access to these large patient populations. Each successful product launch would diversify the company's revenue streams and validate its R&D capabilities, potentially attracting further investment and partnerships within the next 3-5 years.
- Advancement of Soluble Tablet Delivery System: The innovation of a cannabis soluble tablet delivery system offers a distinct competitive advantage. This technology could improve drug absorption, enhance patient compliance due to ease of use, and potentially reduce side effects compared to other delivery methods. The market for novel drug delivery systems is continuously expanding, driven by the need for more effective and patient-friendly pharmaceutical products. If proven successful and patented, this delivery system could be licensed to other companies or integrated into OWC's own product line, creating a valuable asset within the next 2-4 years.
- Leveraging Consulting Services: As more countries and jurisdictions consider or implement medical cannabis programs, the demand for expert guidance on international medical cannabis protocols and regulatory frameworks is increasing. OWC Pharmaceutical's consulting services to private companies and governmental agencies position it to capitalize on this growing need. This segment provides a relatively lower-risk revenue stream compared to drug development and can expand globally as regulatory landscapes evolve. Building a strong reputation in this niche could lead to increased client acquisition and sustained revenue growth over the next 1-3 years.
- Global Medical Cannabis Market Growth: The overarching trend of increasing acceptance and legalization of medical cannabis worldwide provides a broad growth opportunity. The global medical cannabis market is projected to grow at a significant compound annual growth rate, driven by research into new therapeutic applications and changing public perceptions. OWC Pharmaceutical, being solely focused on this sector, is directly aligned with this market expansion. As regulatory barriers diminish and scientific understanding deepens, the addressable market for OWC's potential products will naturally expand, offering long-term growth prospects over the next 5-10 years.
- Strategic Partnerships and Funding: Given the capital-intensive nature of pharmaceutical R&D, securing strategic partnerships with larger pharmaceutical companies or specialized biotech firms, or attracting significant institutional funding, represents a crucial growth opportunity. Such collaborations could provide necessary capital, accelerate clinical development, and offer access to broader distribution networks. A successful funding round or partnership could significantly de-risk OWC's pipeline and expedite its path to commercialization, potentially within the next 1-2 years, enabling the company to scale its operations and research efforts more effectively.
What Are OWCP's Competitive Advantages?
- Specialized R&D focus on specific therapeutic applications of cannabis, building deep expertise in niche areas.
- Proprietary cannabis soluble tablet delivery system, offering a potential advantage in drug efficacy and patient convenience.
- Established consulting services leveraging specialized knowledge in international medical cannabis protocols and regulatory frameworks.
- Potential for intellectual property development around its formulations and delivery methods as its pipeline advances.
What Does OWCP Do?
OWC Pharmaceutical Research Corp., established in 2008 as Dynamic Applications Corp. before adopting its current name in December 2014, operates primarily through its subsidiary, One World Cannabis Ltd. The company is headquartered in Ramat Gan, Israel, and maintains a focused approach on the research and development of cannabis-based medical products. Its core mission revolves around exploring and formulating cannabinoid-derived therapies designed to address a diverse range of medical conditions. These target conditions include serious illnesses such as multiple myeloma, a type of blood cancer, and chronic inflammatory skin conditions like psoriasis. Additionally, OWC Pharmaceutical is actively developing treatments for neurological and pain-related disorders, specifically post-traumatic stress disorder (PTSD), chronic pain, and fibromyalgia, aiming to provide alternative or complementary therapeutic options where traditional treatments may be insufficient or have significant side effects. Beyond its therapeutic pipeline, OWC Pharmaceutical is engaged in innovative drug delivery systems. A key development in this area is its cannabis soluble tablet delivery system, which seeks to enhance the efficacy, bioavailability, and patient convenience of cannabis-based medications. This focus on novel delivery methods underscores the company's commitment to advancing the application of medical cannabis beyond conventional forms. In addition to its R&D activities, OWC Pharmaceutical extends its expertise to a consulting arm. This service provides specialized guidance to both private companies and governmental agencies, advising them on the complex landscape of international medical cannabis protocols and regulatory frameworks. This dual business model allows the company to capitalize on the burgeoning global interest in medical cannabis, not only through product development but also by facilitating its broader adoption and compliant integration into healthcare systems worldwide. With a compact team of 9 employees, OWC Pharmaceutical Research Corp. positions itself as a specialized player in the evolving medical cannabis industry, driven by scientific inquiry and a commitment to therapeutic innovation.
What Products and Services Does OWCP Offer?
- Conducts research and development of cannabis-based medical products.
- Develops therapies targeting multiple myeloma.
- Focuses on cannabis-derived treatments for psoriasis.
- Innovates solutions for post-traumatic stress disorder (PTSD) using cannabinoids.
- Researches and formulates products for chronic pain and fibromyalgia.
- Develops a proprietary cannabis soluble tablet delivery system.
- Provides consulting services on international medical cannabis protocols.
- Offers guidance on regulatory frameworks to private companies and governmental agencies.
How Does OWCP Make Money?
- Generates potential future revenue from the commercialization and sales of its developed cannabis-based medical products.
- Earns income through providing specialized consulting services to private companies regarding medical cannabis protocols.
- Secures revenue by advising governmental agencies on international medical cannabis regulatory frameworks.
- Relies on capital raises and investment to fund its ongoing research and development activities.
What Industry Does OWCP Operate In?
OWC Pharmaceutical Research Corp. operates within the "Drug Manufacturers - Specialty & Generic" industry, a segment of the broader Healthcare sector. Its specific niche is the research and development of cannabis-based medical products, positioning it within the burgeoning global medical cannabis market. This market is characterized by evolving regulatory landscapes, increasing patient acceptance, and significant scientific interest in cannabinoids' therapeutic potential. OWC Pharmaceutical competes with a diverse array of entities, ranging from large pharmaceutical companies exploring cannabinoid derivatives to numerous smaller biotech and cannabis-focused firms. The industry is marked by high R&D costs, lengthy clinical trial processes, and stringent regulatory hurdles. OWC's focus on specific conditions like multiple myeloma and PTSD, coupled with its innovative delivery system, aims to carve out a specialized position. The company also differentiates itself through its consulting services, leveraging expertise in international medical cannabis protocols, which addresses a growing need for guidance in this complex and rapidly expanding industry.
Who Are OWCP's Key Customers?
- Patients suffering from conditions such as multiple myeloma, psoriasis, PTSD, chronic pain, and fibromyalgia, who would use OWC's developed therapies.
- Healthcare providers, hospitals, and pharmacies that would prescribe and dispense the company's medical cannabis products.
- Private companies globally seeking expert guidance on navigating the complexities of medical cannabis regulations and protocols.
- Governmental bodies and agencies requiring consultation on establishing or refining their medical cannabis policies and frameworks.
Financial Health
OWC Pharmaceutical Research Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -31.25 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for OWC Pharmaceutical Research Corp. stands at 237.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 8.03 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
OWC Pharmaceutical Research Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Ramat Gan, IL. The company is led by CEO Ziv Turner. OWCP has traded publicly since 2009.
Insider Activity
The most recent 12 insider filings for OWC Pharmaceutical Research Corp. break down as 12 sales and 0 purchases. On net that is roughly 17.8M shares disposed (about $888K), a signal worth weighing alongside the fundamentals.
OWCP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that executives believe in the growth potential of their cannabis-based therapies.
- Community sentiment has turned positive as discussions around the therapeutic benefits of their products gain traction, reflecting increased public interest.
- The company's ongoing research and development initiatives are promising, positioning them well within the growing medical cannabis market.
- Recent partnerships with healthcare providers enhance their credibility and market reach, fostering optimism among investors and analysts alike.
Bear Case
- Regulatory uncertainties surrounding the cannabis industry continue to loom, creating a cautious atmosphere among potential investors.
- Market perception remains mixed, with some community members expressing skepticism about the scalability of their business model in a competitive landscape.
- Limited financial disclosures have raised concerns about transparency, leading to doubts about the company's operational efficiency and long-term viability.
- Recent volatility in social sentiment indicates that while some are bullish, a significant portion of the community remains wary, suggesting a divided outlook.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
OWCP Latest News
No recent news available for OWCP.
OWCP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OWCP.
Price Targets
Wall Street price target analysis for OWCP.
OWCP MoonshotScore
What does this score mean?
The MoonshotScore rates OWCP 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Ziv Turner
Chief Executive Officer
Ziv Turner serves as the Chief Executive Officer of OWC Pharmaceutical Research Corp., where he is responsible for guiding the company's strategic direction and overseeing its operational execution. In his role, Mr. Turner leads the compact team of 9 employees, focusing on advancing the company's core mission in the research and development of cannabis-based medical products. Specific details regarding his prior career history, educational background, and tenure at other organizations are not provided in the available source data.
Track Record: Under Ziv Turner's leadership, OWC Pharmaceutical Research Corp. has maintained its dedicated focus on developing cannabis-derived therapies for conditions such as multiple myeloma, psoriasis, and PTSD. He oversees the company's efforts in innovating a cannabis soluble tablet delivery system and expanding its consulting services for international medical cannabis protocols. His management of the small team of 9 employees is central to the company's ongoing research and development initiatives.
OWCP OTC Market Information
OWC Pharmaceutical Research Corp. trades on the OTC Other tier, which is the lowest tier of the OTC Markets Group. This tier is typically for companies that do not meet the disclosure or financial standards for OTCQX or OTCQB, or that choose not to provide financial information. Companies on the OTC Other tier are not required to report to the SEC, resulting in significantly less public information and transparency compared to those listed on major exchanges like NYSE or NASDAQ. This classification generally indicates a higher risk profile for investors due to limited oversight and disclosure requirements.
- OTC Tier: OTC Other
- Limited public disclosure and financial transparency, making informed investment decisions difficult.
- High price volatility and low liquidity, leading to challenges in buying or selling shares.
- Increased susceptibility to fraud and manipulation due to less stringent regulatory oversight.
- Difficulty in accessing capital markets, potentially hindering funding for R&D and operations.
- Potential for delisting or further downgrading if disclosure requirements are not met or business operations cease.
- Verify the company's current operational status and any recent news releases directly from their website.
- Attempt to locate any available financial statements or disclosures, even if not SEC-mandated.
- Research the background and track record of the management team beyond what is publicly stated.
- Assess the viability of the company's core business model and the competitive landscape in its niche.
- Investigate any legal or regulatory actions against the company or its executives.
- Evaluate the company's funding sources and cash burn rate, if information is available.
- Understand the specific risks associated with investing in an OTC Other tier stock.
- Clearly stated business model focused on specific R&D in a growing sector (medical cannabis).
- Identified physical headquarters in Ramat Gan, Israel.
- Operates through a named subsidiary, One World Cannabis Ltd.
- Identified CEO, Ziv Turner, leading the company.
- Engagement in consulting services for governmental agencies, suggesting a level of industry recognition.
OWC Pharmaceutical Research Corp. Healthcare Stock: Key Questions Answered
What does OWC Pharmaceutical Research Corp. do?
OWC Pharmaceutical Research Corp., through its subsidiary One World Cannabis Ltd., primarily focuses on the research and development of cannabis-based medical products. The company is dedicated to creating therapies for a range of conditions, including multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD), chronic pain, and fibromyalgia.
What are the main risks for OWCP?
Investing in OWC Pharmaceutical Research Corp. involves several key risks. A primary concern is the substantial capital required for pharmaceutical research and development, coupled with the inherent uncertainty of clinical trial success and regulatory approval. The company faces ongoing challenges in securing sufficient funding, particularly given its OTC Other tier listing, which implies limited liquidity and transparency.
How does OWC Pharmaceutical Research Corp. manage its research and development pipeline?
OWC Pharmaceutical Research Corp. manages its R&D pipeline by focusing on specific therapeutic areas where cannabis-based treatments show promise, such as multiple myeloma, psoriasis, PTSD, chronic pain, and fibromyalgia. The company's strategy involves progressing its drug candidates through various stages of preclinical and clinical development, aiming for eventual regulatory approval.
What is the significance of OWC Pharmaceutical Research Corp.'s soluble tablet delivery system?
OWC Pharmaceutical Research Corp.'s cannabis soluble tablet delivery system holds significant potential as an innovation in the medical cannabis sector. This system aims to improve the administration and efficacy of cannabis-based therapies.
What are the key factors to evaluate for OWCP?
Evaluate OWCP on fundamentals, analyst consensus, and risk factors. OWC Pharmaceutical Research Corp. (OWCP) presents an investment profile centered on its specialized research and development efforts in the rapidly evolving medical cannabis sector. Not financial advice.
How frequently does OWCP data refresh on this page?
OWCP's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OWCP's recent stock price performance?
OWC Pharmaceutical Research Corp. (OWCP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on cannabis-based medical product research and development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OWCP overvalued or undervalued right now?
OWC Pharmaceutical Research Corp. (OWCP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on provided source data. Financial details are limited, particularly for a company trading on the OTC Other tier, which typically has less stringent disclosure requirements. Specific details on CEO background and track record beyond managing employees were not available in the provided data.